|
CDK5RAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6242562850266E-12 |
| Normal-vs-Stage2 |
2.204400E-03 |
| Normal-vs-Stage3 |
5.86799997481791E-09 |
| Normal-vs-Stage4 |
1.555560E-04 |
| Stage1-vs-Stage2 |
8.370000E-01 |
| Stage1-vs-Stage3 |
3.916000E-01 |
| Stage1-vs-Stage4 |
4.824000E-01 |
| Stage2-vs-Stage3 |
5.399400E-01 |
| Stage2-vs-Stage4 |
5.136400E-01 |
| Stage3-vs-Stage4 |
8.909800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
3.807600E-02 |
| Normal-vs-Asian |
4.17260000000752E-05 |
| Caucasian-vs-AfricanAmerican |
1.810980E-01 |
| Caucasian-vs-Asian |
6.488800E-01 |
| AfricanAmerican-vs-Asian |
2.959200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.45300479718003E-11 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
5.449600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.10891329241758E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62614366416847E-12 |
| Normal-vs-Age(61-80Yrs) |
4.02700000000644E-05 |
| Normal-vs-Age(81-100Yrs) |
9.055200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.031000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.884800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.69360000024099E-07 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.305600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.19759996258995E-09 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.424630E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.575300E-03 |
| Classical-VS-Follicular |
1.50419998679041E-09 |
| Classical-VS-Other |
3.249600E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.691950E-02 |
| Tall-VS-Other |
7.797000E-01 |
| Tall-VS-Normal |
8.22710000000226E-05 |
| Follicular-VS-Other |
3.950800E-01 |
| Follicular-VS-Normal |
1.297560E-01 |
| Other-VS-Normal |
1.944820E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.40160105743803E-11 |
| Normal-vs-N1 |
5.371800E-04 |
| N0-vs-N1 |
1.427820E-02 |
|
|
